Search for: "Astrazeneca"
Results 481 - 500
of 1,244
Sort by Relevance
|
Sort by Date
23 Jan 2014, 6:45 pm
A number of similar cases have also filed against AstraZeneca and Bristol-Myers Squibb, involving plaintiffs diagnosed with pancreatic cancer from Onglyzer, another incretin mimetic drug that is not currently joined with the MDL. [read post]
7 Jan 2014, 5:19 pm
Onglyza (saxagliptin) was approved by the FDA in 2009 and is manufactured by Bristol-Myers Squibb and AstraZeneca. [read post]
3 Jan 2014, 7:49 am
Cote entered a damages award in the last of a long-running series of patent infringement actions brought by Astrazeneca against generic drug manufacturers over the active ingredient in Astrazeneca’s brand-name drug Prilosec for heartburn. [read post]
2 Jan 2014, 1:12 pm
§271(e)(2), AstraZeneca had alleged that a drug Hanmi proposed to market falls within claims of U.S. [read post]
30 Dec 2013, 8:50 pm
Noonan -- A classic example of product "evergreening" is how AstraZeneca used its experience with its omeprazole franchise (sold for over a decade as Prilosec®) to promote an alternative form of the drug, Nexium® (particularly, the S-omeprazole enantiomer) as "the little purple pill." [read post]
27 Dec 2013, 4:55 am
AstraZeneca Loses at the Federal Circuit on Omeprazole. [read post]
27 Dec 2013, 4:55 am
AstraZeneca Loses at the Federal Circuit on Omeprazole. [read post]
22 Dec 2013, 8:27 pm
Finally, there's yet another excellent analysis from Stefano Barazza on PatLit, this time in the US Court of Appeals for the Federal Circuit ruling in AstraZeneca v Hanmi (the 'Nexium' case). [read post]
19 Dec 2013, 8:56 pm
The case AstraZeneca v. [read post]
8 Dec 2013, 8:02 pm
Astrazeneca AB et al. v. [read post]
5 Dec 2013, 7:21 am
Astrazeneca AB, et al v. [read post]
13 Nov 2013, 9:14 pm
By Donald Zuhn -- In an appeal decided last month, the Federal Circuit reversed and remanded a decision of noninfringement by the District Court for the District of New Jersey with respect to U.S. [read post]
30 Oct 2013, 5:00 am
Unwired Planet Sues to Enforce Cloud Patents --- DuPont and Heraeus Announce Settlement of Pending Patent Litigation --- Acacia Settles with AstraZeneca on Metered Dose Inhalers --- AK Steel Prevails in Patent Litigation, Does Not Infringe --- Tessera and Sony Settle Litigation --- Taxi Soft Drink Dispenser Sued for Misappropriation of Young Inventor’s Innovation --- CoolTek and Nuance Conclude Patent Infringement Case --- Type 2 Diabetes Royalties Acquired by PDL BioPharma For $240.5… [read post]
30 Oct 2013, 5:00 am
Unwired Planet Sues to Enforce Cloud Patents --- DuPont and Heraeus Announce Settlement of Pending Patent Litigation --- Acacia Settles with AstraZeneca on Metered Dose Inhalers --- AK Steel Prevails in Patent Litigation, Does Not Infringe --- Tessera and Sony Settle Litigation --- Taxi Soft Drink Dispenser Sued for Misappropriation of Young Inventor’s Innovation --- CoolTek and Nuance Conclude Patent Infringement Case --- Type 2 Diabetes Royalties Acquired by PDL BioPharma For $240.5… [read post]
27 Oct 2013, 9:55 pm
Astrazeneca AB et al. v. [read post]
25 Oct 2013, 3:56 am
In the court’s view, this circumstantial evidence of a “pattern of antagonism” raised an inference of retaliation and was enough to support her Title VII claim (Brangman v AstraZeneca, LP). [read post]
19 Sep 2013, 9:53 am
The following post is exclusively the work of the Reed Smith side of the blog.Sometimes the smallest, least significant type of lawsuit can illustrate cracks in the edifice of the largest, most consequential litigation. [read post]
14 Aug 2013, 1:57 pm
We’ve already provided our readers with our list of the testimony (trial and deposition) of the seemingly ubiquitous plaintiff’s expert Dr. [read post]
12 Aug 2013, 10:02 pm
Atkins Foundation, the Ann Arbor Area Community Foundation, the Allen Foundation, AstraZeneca, HealthCare Foundation, Borders Inc, and the Robert Beard Foundation. [read post]
1 Aug 2013, 9:29 am
• Liraglutide (Victoza) marketed by Novo Nordisk • Sitagliptin (Januvia, Janumet & Juvisync) marketed by Merck • Saxagliptin (Onglyza & Kombiglyze) marketed by Bristol-Myers Squibb in partnership with Astrazeneca • Alogliptin (Nesina, Kazano & Oseni) marketed by Takeda Pharmaceuticals • Linagliptin (Tradjenta & Jentadueto) marketed by Eli Lilly and Boehringer Ingelheim While the drug industry continues to ignore or deny the existence of… [read post]
